OKYO Pharma Initiates Phase 2 Trial for Neuropathic Corneal Pain Treatment
OKYO Pharma (NASDAQ: OKYO) has begun patient recruitment for its Phase 2 clinical trial to evaluate OK-101 for treating neuropathic corneal pain (NCP), a rare condition with no FDA-approved treatments. NCP is a chronic pain disorder affecting the eyes, face, or head, believed to result from nerve damage and inflammation. The trial will enroll 48 patients in a randomized, placebo-controlled study to assess pain relief using the Visual Analog Scale (VAS).
The Phase 2 trial follows OK-101’s promising results in dry eye disease, where the treatment demonstrated significant improvements in pain and inflammation. Led by Dr. Pedram Hamrah from Tufts Medical Center, this study marks a key step in addressing the unmet medical need for NCP treatment.
Highlights:
- First FDA-approved IND for NCP: OKYO Pharma’s OK-101 is the first treatment granted an Investigational New Drug (IND) application for NCP.
- $1B+ market: NCP is a significant unmet medical need in ocular care.
- Trial details: 48 patients to participate in a 12-week trial with pain relief as the primary endpoint.
The company aims to build on the drug’s anti-inflammatory and pain-reducing effects observed in prior studies to provide a breakthrough therapy for patients suffering from NCP.
